Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Hepatitis C Virus | Current Treatment | EU5 | 2017

Login to access report north_east
Contact sales account_box

Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma in the EU5 and a common indication for liver transplantation. The 2013-2015 EMA authorizations of Gilead’s Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir), combined with Bristol-Myers Squibb’s Daklinza (daclatasvir) and AbbVie’s Viekirax +/- Exviera (ombitasvir/paritaprevir/ritonavir +/- dasabuvir), have ushered in the era of IFN-free therapy for chronic HCV and completely reshaped the HCV therapeutic market. Recent EMA approvals of Gilead’s Epclusa (sofosbuvir/velpatasvir) and Merck & Co’s Zepatier (elbasvir/grazoprevir) provide additional IFN-free options for EU5 HCV patients. Taken together, currently approved regimens provide efficacious IFN-free options for most HCV genotypes in the EU5. This research focuses on current and anticipated use of HCV regimens, including IFN-free and remaining IFN-based regimens, by capturing patient-share data, current prescribing trends, and anticipated changes in prescribing and treatment. We also evaluate physician-perceived drivers and obstacles to the uptake of key brands.

Questions Answered in This Report:

What factors influence physicians’ treatment and management of chronic HCV infections?

What are the major drug attributes driving physicians to prescribe certain brands?

What obstacles prevent physician prescribing of key HCV therapies?

How do physicians anticipate their prescribing of different therapies to change in the next six months?

Scope:

Markets covered: France, Germany, Italy, Spain, and United Kingdom

Methodology: Survey of 89 gastroenterologists and 162 hepatologists; approximately 50 respondents per EU5 country

Key drugs covered: Incivo, Victrelis, Sovaldi, Olysio, Daklinza, Harvoni, Viekirax + Exviera, Zepatier, Epclusa, glecaprevir/pibrentasvir, sofosbuvir/velpatasvir/voxilaprevir

Key companies mentioned: AbbVie, Bristol-Myers Squibb, Gilead, Merck & Co., Janssen, Johnson & Johnson, Roche

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Current Treatment: Physician Insights – Major Depressive Disorder (EU5)
Across the EU5, the treatment landscape for major depressive disorder (MDD) is shaped by the widespread use of SSRIs and SNRIs, which continue to serve as firstline therapy due to their…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east